The ShiftShapers Podcast
Change either paralyzes or energizes - the choice is yours. Hear from businesses and entrepreneurs who have become energized and who have profited by shaping the shifts in their markets and practices. Become a SHIFTSHAPERS INSIDER and get our latest download, advance notice of all podcasts, podcast summaries, and special INSIDER-ONLY content. INSIDER SIGN UP
The ShiftShapers Podcast
Ep #73: Using Reinsurance for Pharmacy Costs to Mitigate Overall Health Spend - With Crystal Williams
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
In the post-ACA environment we have seen intensely increased interest in self insured financing arrangements. Some elements of self-insurance are now making their way out as stand-alone components, and are even being applied to fully-insured plans. Our guest and subject matter expert, Crystal Williams, President of RxReins joins us to discuss reinsuring one of the biggest cost drivers in any plan: pharmacy.
In this episode of The ShiftShapers podcast, Crystal explains the basics of stop loss coverage. We explore strategies and tactics that advisors can use when discussing this cost driver with prospects and clients. Crystal also gives us the carrier’s perspective on this unique strategy as applied to fully-insured plans. This is a novel conversation that will help you to differentiate yourself and deliver value-added intelligence for your clients.
What You’ll Learn From This Episode:
- The basics of stop loss coverage.
- Whether it is unusual to apply stop loss to pharma only.
- How this can work with fully insured plans.
- The impact of this type of arrangement.
- What to benefit advisors need to know to discuss this with their prospects and clients.
How can reinsurance of pharmacy costs on stealth and fully insured plans help you bend your clients' overall health spend? We'll find out on this episode of Shift Shapers.
SPEAKER_01Either paralyzes or energizes. The choice is yours. You're listening to the Shift Shapers podcast. You're about to learn firsthand from businesses and entrepreneurs who have successfully shaped the shifts in their industry. Get ready to become the change that you want to see. Here's your host and chief transformation strategist, David Salt Smith.
DavidThe Protect Plans are proud to sponsor this episode of Shift Shapers in honor of brokers like you. Brokers committed to bringing their clients cutting-edge healthcare coverage. The Protect Plans are safe and simple, fixed-cost, self-funded medical coverage with wellness and transparency built in. Learn more at www.protectplans.info. There's been a lot of interest in self-insurance, and we've done a number of podcasts about different aspects of self-insurance. And because of all of the interest, there seem to be some components of self-insurance that you might know of on a traditional self-insured plan, but some components that are now making their way out as standalone components and even in cases being applied to fully insured plans. We asked Crystal Williams, president of RX Reens, to join us today to talk about that. Thank you, Crystal. Thank you for joining us.
SPEAKER_00Hi, David. Thank you for having me.
DavidLet's level set. I know that some of our listeners are very familiar with self-insurance and some of them aren't. We're going to be talking a lot about stop loss. What in a nutshell, what is stop loss insurance?
SPEAKER_00Stop loss insurance is a financial contract that protects employers who self-fund their employee health benefits. It protects them from any type of catastrophic loss from either one individual or high utilization from the group as a whole.
DavidGreat simple explanation. And that's a good level set. That's a good place to start. Now, reinsurance in a traditional setting is usually applied to medical claims or all claims, if you will, including medical and pharma. You've developed a notion and a specialization around using stop loss for pharmacy only. How does that work?
SPEAKER_00That's correct. Prescription drug has much higher trends. There's especially with the development of specialty drugs, there's a lot more risk associated with prescription drugs than in the past. So what we've done is we've designed a program to help employers manage their prescription drug spend either on a carve out from their fully insured plan or even a carve out from their medical spec policy.
DavidInteresting. Now, when we think about stop loss, we think about it for self-insured plans. And clearly there's an application there. Are most of the concerns, the employers, if you will, that are using this kind of a tool using it on self-funded plans?
SPEAKER_00Yes. Well, initially, the majority of our clients, they are traditionally fully insured. However, they're seeing some interest within the self-insured market, and there's something about it that triggers their interest. So carving out your prescription drug from your fully insured medical plan is a great introduction to the self-insurance world. So by having a stop loss policy available for those employers who want to carve out their RX program, it gives them more of a comfort level and introduces them into that self-funding arena.
DavidThat's interesting. So it can not only be a viable tool, but it can be kind of a toes go in the water first thing for folks who, employers who may be considering a fully self-insured plan?
SPEAKER_00Correct. Typically, what we see is about two to three years after they've self-funded their prescription drug plan, they understand how the mechanics work, and then they'll start considering self-insuring their whole entire medical plan.
DavidInteresting. I'll bet there are an awful lot of advisors who aren't aware that, at least in some instances, they can go and talk to a fully insured carrier and ask them to carve out the pharmacy. Let's explore that a little bit. Is there a particular size of group at which that becomes a viable question to go and talk to a carrier about?
SPEAKER_00It really depends on the carrier. It's typically groups over 100 employees. The reason why is groups under 100, they're typically community rated and claims experience isn't available. Just because claims experience isn't available doesn't mean that that case can't be underwritten or qualify for a stop-loss insurance policy. It's just there's a lot more manual underwriting involved. So to go back to your question, 100 is usually the sweet spot, 100 and up.
DavidWhat kind of plans lend themselves? I mean, is this something that you can do with any kind of plan, whether it's a PPO or an HMO, or are our certain kinds of fully insured plans more attuned to using this kind of a mechanism?
SPEAKER_00What we found is, and this again is it really depends on what state you're in and how dominant those fully insured carriers are in your state. Just to give you an example, in the state of California, Southern California has a really is really HMO dominant. So it's a little bit more difficult to have the carrier, for the carrier to allow a carve out from the prescription drug plan. You'll encounter much more resistance than, for example, Northern California, which is primarily a PPO-driven area. The PPO plans and the carriers who manage those PPO plans, they're much more willing to carve out the prescription drug plan.
DavidOne of the things that we've heard for years in the fully insured marketplace for other kinds of external programs, if you want, that carriers also do, is that carriers were reticent to do them because there wasn't a good mechanism for the carriers to get data back from the external plan, whether it's an on-site clinic or some other mechanism like that. When you take a plan and you self-insure the pharmacy or you reinsure, if you will, the pharmacy, are there mechanisms now that that feed all that pharma info back to the case review and other people at the carrier, at the fully insured carrier?
SPEAKER_00Absolutely. PBMs, the PBMs have such great technology these days that, and this brings me to a good point of uh some of the brokers may be concerned that by carving out the RX, the max out-of-pocket may not be properly reported or may be difficult to track. Well, PBMs have such great technology these days that that's never an issue. A data feed is constant and it's always fed to the medical carrier. And the data that's provided from a PBM, it provides very intricate details so that you can tell a history of somebody's condition as well as their prevalence of use. And there's a lot of really good information that can be distributed to several different entities that would need to analyze this type of the prescription drug data.
DavidAs you can tell, I'm intrigued by this notion. You work with benefit advisors. When they go off and they have conversations with fully insured carriers, what are they telling you those conversations are like?
SPEAKER_00It can go two ways. It can go a very positive, positive conversation and where the carrier is very open to allowing the broker to carve out the prescription drug plan, or the broker could encounter much more resistance. So when we get feedback from the broker that there's much more resistance, what we found is we work with the broker to help them leverage perhaps their block of business. And what we found is by leveraging your block of business between two fully insured carriers on the medical side, one carrier is more likely to release the data for the Rx and allow a carve out than the other. So there's some strategic tactics that come along with assisting brokers and helping them to carve out their RX plan.
DavidWe'll get back to the strategic tactics because I think that's a fascinating piece to talk about. But do you find that the carrier willingness to do this is based more on carrier culture in general, or is it driven by their dominance in a particular market? Or both?
SPEAKER_00It's both. If you would encounter resistance from a carrier, most likely the reason why is that the carrier is profiting from the prescription drug plan. There's a lot of funds that are hidden within a prescription drug plan when it's fully insured. There's rebates, there's spread on discounts, there's also different plan design mechanisms that the carrier is profiting from and the employer is not. That's one of the reasons why a carrier would resist in allowing a carve out. Another area would be the employer or the carrier wants to carve out the RX program because they're a little uncertain about the risk. There's a lot of these new specialty drugs as well as the uh the new PCS K9 drugs that they may not want to take the risk on or they may not know how to underwrite.
DavidThose PCS K9 drugs you're talking about are a new class of cholesterol drugs that are coming to market.
SPEAKER_00Correct. And and what's unique about the PSK9 drugs is they will impact a large portion of the population. You may have seen in the last year the drug Sivaldi, which is the hepatitis C drug, that's impacted one to two percent of the population. I typically see one patient per case that I have. And uh that impacts the group based upon one person. However, these PSK9 drugs, they're four conditions that are so common that we won't see an impact from one or two people. It'll be a large portion of the population. So for conditions, cholesterol conditions that may have cost $500 a year or even under $5,000 a year, because a lot of the medications for cholesterol right now, they're generics. Now we're moving on to these injectable drugs that could cost the employer about $14,000 a year. So we're expecting a pretty large impact from these PSK9 drugs coming on the prescription drug plans.
DavidAre they more effective? I mean, over time, are would you expect that even with that increased spend there would be a concomitant decrease in pharmacy spend and medical trend?
SPEAKER_00It's hard to say. We don't have the data yet, and the data isn't out there. It was only in until the last couple of months that we actually found out what the true cost was going to be. There's a new drug called Proluent, and it originally was projected to cost $7,000 to $12,000 a year. However, that when the drug manufacturer released a drug, it's closer to about $14,000.
DavidOuch. That will certainly make a dent in pharmacy spend.
SPEAKER_00Well, and and being that it affects such a large portion of the population, it will definitely have an impact.
DavidAnd now a word from our sponsor. The Protect Plans, a safe and simple fixed-cost self-funded medical coverage program with refund assistors, is getting a lot of attention. And that's not surprising given the growing popularity of level premium plans and the fact that the Protect plans arrive with a whole new approach. The well-deserved buzz about the Protect Plan is from more than just the included wellness and transparency programs, and it's about more than their competitive pricing, strong national network from Aetna, AM best-rated A stop loss carriers, and sophisticated underwriting. What's really intriguing about the Protect Plans is how they seem to hit that sweet spot you need for your clients. The people behind the Protect plans say that's because they listened to brokers while designing the program. That's not really surprising, given that two of those behind the Protect Plans are Trey Wilde and Alan Katz, both past NAHU presidents. We've been listening to and supporting brokers for decades. To see what happens when a health plan actually listens to brokers, head on over to www.protectplans.info. After the conclusion of the podcast, of course, PBMs and companies are used to managing some of those drugs. For example, Embrill comes to mind, but that's significantly less expensive on a monthly dosage than what you're talking about. So it's kind of interesting that this is a whole new frontier. Let's go back to the strategies and tactics that you you mentioned earlier. What are some of those and what do advisors need to know?
SPEAKER_00Advisors really should stay proactive instead of reactive when it comes to the prescription drug plan. In the upcoming years, they anticipate that 50% of the prescription drug cost will be specialty drug medications. And these new PSCK9s do fall under the specialty drug category. So what we suggest and what we tell our benefit advisors is work with your PBM and understand what types of programs are in place to help manage these costs. For example, these PSK9 drugs, they may not be for everybody. A certain amount of the population would qualify for these drugs initially, and some of them wouldn't. So put the proper step therapies in place, put the proper prior authorizations in place to make sure that the people who really need these drugs are getting these drugs. And the people that are doing well on their traditional therapies, keep them on the traditional therapies until they need improvement.
DavidWe're talking about all of these expensive drugs, some of them here, some of them coming. What can a benefit advisor expect to see in terms of a premium reduction from a fully insured carrier that agrees to carve out pharmacy?
SPEAKER_00Typically, the prescription drug spend is about 30%. Right now, about 30% of the medical spend. The carrier should give them about 20 to 30% credit, but we know that probably won't happen, especially since the carrier will be losing some revenue by carving out the RX plan via rebates and spreads and discounts and things like that. We know that the carrier won't give them 20 to 30%. What we'll see is closer to about 10%, which is pretty attractive when you're carving out your prescription drug plan. Because now, as you carve out, you have the opportunity to save more by implementing mandatory generic programs, utilization programs, step therapy, the ability to customize your formulary, customize your plan designs. So the savings is much more than what the carrier will provide.
DavidWe ask this question about most things these days, so we'll ask it about this. Has ACA increased interest in this kind of a strategy?
SPEAKER_00Absolutely. ACA has triggered interest in the self-funded industry altogether, let alone the employers are now more focused and more involved in their health benefits. So by promoting more focus on your prescription drug program, we believe that any savings had in the prescription drug program will then trigger savings on the medical side.
DavidSo let's switch gears a little bit and talk a little. We talked about what the what the conversation with a carrier might look like. As you teach benefit advisors how to employ the strategy with their prospects and clients, what do those conversations look like? I mean, I know for some employers, doing anything different than they've done for arguably since World War II becomes a scary prospect. How do you coach advisors? How do they get over that and help their clients get over taking that first step?
SPEAKER_00The conversation that the broker would have with the employer is, first off, explaining to the employer the options that they have in the self-insurance market and introducing them into a self-insurance concept by carving out their Rx and also explaining to an employer the potential savings that can be had by absorbing rebates, negotiating your PBM contract, implementing utilization programs, mandatory generic programs.
DavidWe talked a little bit earlier about the minimum size of a case at being about 100, and that's largely driven by whether you can get claims data or not. Are jumbo cases doing this already? Have they been doing it large and big, for example, maybe municipal cases have been doing this for a long time already? Or is this new to all segments?
SPEAKER_00This is something that large employers have been doing for quite some time. But the large employers, specifically municipalities, they're still purchasing stop loss insurance for the prescription drug programs because number one, you you can't put the taxpayers' money at risk. So they have some type of open liability that they have to cap. But also, we're starting to receive some interest from some private large self-insured employers who are really concerned about these PCSK9 drugs as well as the new specialty drugs hitting the market.
DavidWhen you work with benefit advisors, do you also talk a lot about utilization strategies, compliance strategies, et cetera?
SPEAKER_00Absolutely. We have no financial interest besides just helping employers and brokers and educating them on the different ideas and the different strategies that they can do with their prescription drug plan, even in terms of co-pays and utilization management programs. Because we're underwriters and we underwrite on a daily basis, we see all different types of plan designs, different shapes, different sizes, and for different size and polar groups. So we'd like to give our expertise and what we see in the marketplace as recommendations to help them control their prescription drug cost.
DavidCrystal, in the minute or two that we have left in the interview, we always like to ask all of our subject matter experts what they see for the future. What do you see coming down the road in this area in particular? And you can define the future as you know, near-term, midterm, long-term if you'd like.
SPEAKER_00The short term is really when employers and benefit advisors need to be proactive instead of reactive and really tighten up those formularies. And they're going to see some utilization increases and some cost increases in the next two to three years. But one of the things to keep in mind is that there are a lot of these specialty medications that have been on the market that are now starting to compete up against a biosimilar product. So there is some relief in the future. It may not be immediate, but as technology evolves and as the patents run out for some of these higher cost medications, the employers may start to see some relief. Absolutely.
DavidGreat place to leave our discussion, Crystal Williams, president of RX Greens. Crystal, we we thank you for your sharing your expertise with the Shift Shapers audience and hope you'll come back.
SPEAKER_00Thank you, David. I appreciate it.
DavidThe Shift Shapers Podcast is a production of the Salzman Group. We work with entrepreneurs, executives, and companies, just like you, to help shape the shifts in your business. To schedule a 20-minute call to learn more, visit our website at thesaltzmangroup.com. Or call me directly at 803-386-8005. I'd love to hear from you. And while you're on our site, you can also click the podcast tab for the entire catalog of Shift Shapers episodes and to access some really great special offers. Give me a call at 803 386 8005 and learn how to put the secrets of the ship shapers to work in your business.